Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Combined With Vinorelbine in HER2-positive Metastatic Breast Cancer
NCT04605575Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2020
- Primary completion
- Aug 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04605575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605575.